ASC Therapeutics, a privately-owned biopharmaceutical company specializing in the development of in-vivo gene replacement, gene editing, and allogeneic cell therapies

REGENXBIO Inc. celebrated a major milestone as the first patient received RGX-202 at dose level 2 in the Phase I/II AFFINITY DUCHENNE® trial. This trial is investigating RGX-202, a novel

Ensysce Biosciences, Inc. and OncoZenge AB have recently announced the signing of a letter of intent (LOI) to explore a strategic collaboration for the accelerated

TOLREMO therapeutics AG has announced the initiation of its Phase 1 clinical trial, with the dosing of the first patient taking place. This trial is designed to assess the safety, tolerability,

Recce Pharmaceuticals Limited has officially received approval from the Canadian Patent Office for a new patent titled "Process for Preparation of Biologically Active Copolymer

Arcturus Therapeutics Holdings Inc. has recently announced that the U.S. Food and Drug Administration granted Orphan Drug Designation for ARCT-032, the company's product candidate for treating cystic fibrosis

Hemogenyx Pharmaceuticals plc has made a noteworthy expansion in the potential applications of its Chimeric Bait Receptor platform. Initially designed for treating viral diseases

Simcere Pharmaceutical Group Limited recently finalized an exclusive license and collaboration agreement with Connect Biopharma HongKong Limited concerning Rademikibart, an innovative IL-4Rα monoclonal antibody

Immutep Limited has expanded the INSIGHT-003 trial to include four sites across Germany, including the University Clinic of Ruhr Universität Bochum and the Lung Clinic Cologne-Merheim

Immutep Limited has expanded the INSIGHT-003 trial to include four sites across Germany, including the University Clinic of Ruhr Universität Bochum and the Lung Clinic Cologne-Merheim.